Evidence map›Paper›PMID 35992101›Full record

ArticleFrontiers in endocrinology2022

Melatonin alleviates renal injury by activating mitophagy in diabetic nephropathy.

Hanfen Tang, Ming Yang, Yinghong Liu, Xuejing Zhu, Shiping Liu, Hong Liu, Lin Sun, Panai Song

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hanfen TangDepartment of Nephrology, Second Xiangya Hospital, Central South University, Changsha, China.
Ming YangDepartment of Nephrology, Second Xiangya Hospital, Central South University, Changsha, China.
Yinghong LiuDepartment of Nephrology, Second Xiangya Hospital, Central South University, Changsha, China.
Xuejing ZhuDepartment of Nephrology, Second Xiangya Hospital, Central South University, Changsha, China.
Shiping LiuDepartment of Nutrition, Second Xiangya Hospital, Central South University, Changsha, China.
Hong LiuDepartment of Nephrology, Second Xiangya Hospital, Central South University, Changsha, China.
Lin SunDepartment of Nephrology, Second Xiangya Hospital, Central South University, Changsha, China.
Panai SongDepartment of Nephrology, Second Xiangya Hospital, Central South University, Changsha, China.
Second Xiangya Hospital of Central South University · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic nephropathy (DN) causes serious renal tubule and interstitial damage, but effective prevention and treatment measures are lacking. Abnormal mitophagy may be involved in the progression of DN, but its upstream and downstream regulatory mechanisms remain unclear. Melatonin, a pineal hormone associated with circadian rhythms, is involved in regulating mitochondrial homeostasis. Here, we demonstrated abnormal mitophagy in the kidneys of DN mice or high glucose (HG)-treated HK-2 cells, which was accompanied by increased oxidative stress and inflammation. At the same time, the melatonin treatment alleviated kidney damage. After mitochondrial isolation, we found that melatonin promoted AMPK phosphorylation and accelerated the translocation of PINK1 and Parkin to the mitochondria, thereby activating mitophagy, reducing oxidative stress, and inhibiting inflammation. Interestingly, the renal protective effect of melatonin can be partially blocked by downregulation of PINK1 and inhibition of AMPK. Our studies demonstrated for the first time that melatonin plays a protective role in DN through the AMPK-PINK1-mitophagy pathway.

Indexed as

Diabetes MellitusDiabetic NephropathiesMelatoninAMP-Activated Protein KinasesAnimalsInflammationKidneyMiceMitophagyAMP-Activated Protein KinasesMelatonindiabetic nephropathy (DN)melatoninmitophagyp-AMPKrenal tubular injury

Identifiers

PMID35992101
PMCPMC9388821
OpenAlexW4289877245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.